Evidence map›Paper›PMID 38231018›Full record

ArticleBlood advances2024

Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data.

Flores Weverling, Mieke Roeven, Clara Nijssen, Annoek E C Broers, Elisabeth Dovern, Anna van Rhenen, Geerte van Sluis, Carin L E Hazenberg, Peter van Balen, Maria T Kuipers and 5 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Flores WeverlingDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0009-0001-7429-0616
Mieke RoevenDepartment of Hematology, Radboud University Medical Center; Nijmegen, The Netherlands.
Clara NijssenDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
Annoek E C BroersDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Elisabeth DovernDepartment of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.ORCID 0000-0003-0905-1907
Anna van RhenenDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
Geerte van SluisDepartment of Hematology, Isala Hospital, Zwolle, The Netherlands.
Carin L E HazenbergDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
Peter van BalenDepartment of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Maria T KuipersDepartment of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Karen M K de VooghtCentral Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands.
Linde MorsinkDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0001-5408-5298
Jürgen KuballDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-3914-7806
Erfan NurDepartment of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.ORCID 0000-0002-7069-930X
Moniek A de WitteDepartment of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0001-7470-2994
University Medical Center Utrecht · NLAmsterdam University Medical Centers · NLUniversity Medical Center Groningen · NLErasmus MC Cancer Institute · NLIsala · NLLeiden University Medical Center · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Red-Cell Aplasia, PureAntibodies, MonoclonalHumansTransplantation, HomologousAntibodies, Monoclonaldaratumumab

Identifiers

PMID38231018
PMCPMC11006807
OpenAlexW4390954873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.